Rock Springs Capital Management’s Spyre Therapeutics SYRE Stock Holding History

Rock Springs Capital Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.75M	Buy	+42,254	New	+$3.08M	0.18%	78
2023 Q4	–	Sell	-136,556	Closed	-$1.67M	–	114
2023 Q3	$1.67M	Hold	136,556	–	–	0.04%	101
2023 Q2	$1.54M	Hold	136,556	–	–	0.04%	109
2023 Q1	$990K	Hold	136,556	–	–	0.02%	112
2022 Q4	$1.54M	Hold	136,556	–	–	0.04%	108
2022 Q3	$1.8M	Buy	136,556 +13,675	+11%	+$169K	0.05%	114
2022 Q2	$1.55M	Buy	122,881 +50,424	+70%	+$1.77M	0.05%	119
2022 Q1	$4.17M	Buy	72,457 +9,365	+15%	+$786K	0.1%	108
2021 Q4	$7.49M	Hold	63,092	–	–	0.17%	103
2021 Q3	$12.5M	Hold	63,092	–	–	0.26%	97
2021 Q2	$11M	Hold	63,092	–	–	0.22%	107
2021 Q1	$12.5M	Sell	63,092 -108	-0.2%	-$20.7K	0.27%	98
2020 Q4	$12.4M	Sell	63,200 -421	-0.7%	-$87.3K	0.26%	103
2020 Q3	$11.3M	Hold	63,621	–	–	0.29%	96
2020 Q2	$14.7M	Buy	63,621 +31,621	+99%	+$6.02M	0.4%	86
2020 Q1	$3.73M	Hold	32,000	–	–	0.15%	110
2019 Q4	$6.11M	Hold	32,000	–	–	0.19%	102
2019 Q3	$6.15M	Hold	32,000	–	–	0.25%	94
2019 Q2	$5.48M	Hold	32,000	–	–	0.2%	98
2019 Q1	$6.44M	Buy	32,000 +6,000	+23%	+$1.25M	0.25%	99
2018 Q4	$4.87M	Hold	26,000	–	–	0.23%	96
2018 Q3	$6.22M	Hold	26,000	–	–	0.23%	105
2018 Q2	$6.88M	Buy	26,000 +5,036	+24%	+$1.24M	0.26%	104
2018 Q1	$5.2M	Hold	20,964	–	–	0.22%	117
2017 Q4	$2.83M	Hold	20,964	–	–	0.13%	126
2017 Q3	$2.58M	Hold	20,964	–	–	0.12%	122
2017 Q2	$2.01M	Hold	20,964	–	–	0.1%	131
2017 Q1	$3.9M	Hold	20,964	–	–	0.23%	98
2016 Q4	$2.28M	Hold	20,964	–	–	0.15%	110
2016 Q3	$3.36M	Hold	20,964	–	–	0.21%	105
2016 Q2	$2.55M	Buy	+20,964	New	+$4.02M	0.19%	108

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rock Springs Capital Management's SYRE Position: Q2 2026 in Review

Rock Springs Capital Management opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 42,254 shares worth $3.75M. The stake represents 0.18% of the portfolio and ranks #78 among its holdings. This is a return to the name: Rock Springs Capital Management previously reported a position in SYRE as recently as Q3 2023.

Rock Springs Capital Management first reported a position in SYRE in Q2 2016 and has held it in 31 quarters since. The position peaked at $14.7M in Q2 2020. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Rock Springs Capital Management held 42,254 shares of Spyre Therapeutics worth $3.75M as of Q2 2026.
Spyre Therapeutics was a new Rock Springs Capital Management position in Q2 2026.
Spyre Therapeutics made up 0.18% of Rock Springs Capital Management's portfolio in Q2 2026, its #78 holding.
Rock Springs Capital Management first reported a position in Spyre Therapeutics in Q2 2016 and has held it in 31 quarters since.
Rock Springs Capital Management's Spyre Therapeutics position peaked at $14.7M in Q2 2020.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.